Corium
Jeffrey Gaffey has over 20 years of experience in financial planning and analysis. Jeffrey is currently the VP and Head of FP&A at Corium, Inc. Prior to this, they served as the Head of FP&A at Apellis Pharmaceuticals and Executive Director of Financial Planning Analysis at Epizyme. Jeffrey also held roles such as Director of FP&A at Merrimack and Associate Director of FP&A at Synageva BioPharma Corp. Jeffrey has extensive experience in financial management, business partnering, and implementing financial systems and processes. Early in their career, they worked at Sanofi Genzyme, Vertex Pharmaceuticals, Bristol-Myers Squibb, RIGHTNOW TECHNOLOGIES, and STATE STREET CORPORATION, where they gained valuable experience in finance and accounting analysis, sales forecasting, and international equities.
Jeffrey Gaffey obtained a Bachelor of Science degree in Economics and Finance from Boston College, which they completed from 1996 to 2000.
Corium
Corium is a commercial-stage biopharmaceutical company that is leading the development and commercialization of central nervous system (CNS) healthcare therapies that provide clinicians with important treatment options for patients, their families, and their caregivers. Collaborating with some of the world's largest pharmaceutical and consumer product companies, we have a track record and depth of experience in taking products from concept, through development, to manufacturing and final commercialization.